Loading…

Local Effects of Two Intravenous Formulations of Pulmonary Vasodilators on Airway Epithelium

Intravenous formulations of epoprostenol are frequently delivered via nebulizer to treat pulmonary hypertension in acutely ill patients. Although their efficacy as pulmonary vasodilators has been shown to be comparable to inhaled nitric oxide, the local effects of these formulations within the airwa...

Full description

Saved in:
Bibliographic Details
Published in:Respiratory care 2020-10, Vol.65 (10), p.1427-1432
Main Authors: Kuch, Bradley A, Linssen, Rosalie, Yoshikawa, Hiroki, Smallwood, Craig D, Davis, Michael D
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c388t-1dbc86c1d5a997f0bdc8edfa5602e1bd3dc7c1dc7dde3be1b9e39d3ed38de1a73
container_end_page 1432
container_issue 10
container_start_page 1427
container_title Respiratory care
container_volume 65
creator Kuch, Bradley A
Linssen, Rosalie
Yoshikawa, Hiroki
Smallwood, Craig D
Davis, Michael D
description Intravenous formulations of epoprostenol are frequently delivered via nebulizer to treat pulmonary hypertension in acutely ill patients. Although their efficacy as pulmonary vasodilators has been shown to be comparable to inhaled nitric oxide, the local effects of these formulations within the airways have not been determined. We hypothesized that the alkaline diluents of these compounds would lead to increased airway epithelial cell death and ciliary cessation. Human bronchial epithelial cells were exposed to epoprostenol in glycine and arginine diluents or control fluid. Ciliary beat frequency, lactate dehydrogenase, and total RNA levels were measured before and after exposure. Results were compared between exposure and control groups. Ciliary beat frequency ceased immediately after exposure to epoprostenol with both diluents. Lactate dehydrogenase levels increased by 200% after exposure to epoprostenol and glycine diluent ( = .002). Total RNA levels were undetectable after exposure to epoprostenol and arginine, indicating complete cell death and lysis ( = .015). Ciliary beat frequency ceased after 30 s of exposure to epoprostenol and glycine ( = .008). There was no difference between cells exposed to epoprostenol and those exposed only to diluent. Exposure to intravenous formulations of epoprostenol in glycine and arginine caused increased cell death and ciliary cessation in bronchial epithelial cells. These findings suggest that undesired local effects may occur when these compounds are delivered as inhaled aerosols to patients.
doi_str_mv 10.4187/respcare.07938
format article
fullrecord <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracmisc_A638437453</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A638437453</galeid><sourcerecordid>A638437453</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-1dbc86c1d5a997f0bdc8edfa5602e1bd3dc7c1dc7dde3be1b9e39d3ed38de1a73</originalsourceid><addsrcrecordid>eNptUc1LwzAUD6K4Ob16lILgrTNp-pEex9h0MNDD9CSUNHlxkbYpSevYf2_cnCiMd3i89_vg8X4IXRM8jgnL7i24VnALY5zllJ2gIcljGtI0iU_REOMIh4RG8QBdOPfhxzRO8nM0oFFCGGZsiN6WRvAqmCkFonOBUcFqY4JF01n-CY3pXTA3tu4r3mnT7PDnvqpNw-02eOXOSO0hYz3SBBNtN3wbzFrdraHSfX2JzhSvHFz99BF6mc9W08dw-fSwmE6WoaCMdSGRpWCpIDLheZ4pXErBQCqepDgCUkoqReZRkUkJtPSbHGguKUjKJBCe0RG63fu-8woK3Sjjzxe1dqKYpJTFNIsT6lnjIyxfEmotTANK-_0_wd0fwRp41a2dqfrdK446C2ucs6CK1urav6gguPiOqTjEVOxi8oKbvaDtyxrkL_2QC_0C2BiQ-w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Local Effects of Two Intravenous Formulations of Pulmonary Vasodilators on Airway Epithelium</title><source>Open Access: PubMed Central</source><creator>Kuch, Bradley A ; Linssen, Rosalie ; Yoshikawa, Hiroki ; Smallwood, Craig D ; Davis, Michael D</creator><creatorcontrib>Kuch, Bradley A ; Linssen, Rosalie ; Yoshikawa, Hiroki ; Smallwood, Craig D ; Davis, Michael D</creatorcontrib><description>Intravenous formulations of epoprostenol are frequently delivered via nebulizer to treat pulmonary hypertension in acutely ill patients. Although their efficacy as pulmonary vasodilators has been shown to be comparable to inhaled nitric oxide, the local effects of these formulations within the airways have not been determined. We hypothesized that the alkaline diluents of these compounds would lead to increased airway epithelial cell death and ciliary cessation. Human bronchial epithelial cells were exposed to epoprostenol in glycine and arginine diluents or control fluid. Ciliary beat frequency, lactate dehydrogenase, and total RNA levels were measured before and after exposure. Results were compared between exposure and control groups. Ciliary beat frequency ceased immediately after exposure to epoprostenol with both diluents. Lactate dehydrogenase levels increased by 200% after exposure to epoprostenol and glycine diluent ( = .002). Total RNA levels were undetectable after exposure to epoprostenol and arginine, indicating complete cell death and lysis ( = .015). Ciliary beat frequency ceased after 30 s of exposure to epoprostenol and glycine ( = .008). There was no difference between cells exposed to epoprostenol and those exposed only to diluent. Exposure to intravenous formulations of epoprostenol in glycine and arginine caused increased cell death and ciliary cessation in bronchial epithelial cells. These findings suggest that undesired local effects may occur when these compounds are delivered as inhaled aerosols to patients.</description><identifier>ISSN: 0020-1324</identifier><identifier>EISSN: 1943-3654</identifier><identifier>DOI: 10.4187/respcare.07938</identifier><identifier>PMID: 32518088</identifier><language>eng</language><publisher>United States: Daedalus Enterprises, Inc</publisher><subject>Administration, Inhalation ; Analysis ; Antihypertensive Agents - adverse effects ; Care and treatment ; Cell death ; Epithelium ; Epoprostenol ; Epoprostenol - therapeutic use ; Glycine ; Humans ; Hypertension ; Hypertension, Pulmonary - drug therapy ; Nitric oxide ; Nitric Oxide - therapeutic use ; RNA ; Vasodilation ; Vasodilator Agents</subject><ispartof>Respiratory care, 2020-10, Vol.65 (10), p.1427-1432</ispartof><rights>Copyright © 2020 by Daedalus Enterprises.</rights><rights>COPYRIGHT 2020 Daedalus Enterprises, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c388t-1dbc86c1d5a997f0bdc8edfa5602e1bd3dc7c1dc7dde3be1b9e39d3ed38de1a73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32518088$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kuch, Bradley A</creatorcontrib><creatorcontrib>Linssen, Rosalie</creatorcontrib><creatorcontrib>Yoshikawa, Hiroki</creatorcontrib><creatorcontrib>Smallwood, Craig D</creatorcontrib><creatorcontrib>Davis, Michael D</creatorcontrib><title>Local Effects of Two Intravenous Formulations of Pulmonary Vasodilators on Airway Epithelium</title><title>Respiratory care</title><addtitle>Respir Care</addtitle><description>Intravenous formulations of epoprostenol are frequently delivered via nebulizer to treat pulmonary hypertension in acutely ill patients. Although their efficacy as pulmonary vasodilators has been shown to be comparable to inhaled nitric oxide, the local effects of these formulations within the airways have not been determined. We hypothesized that the alkaline diluents of these compounds would lead to increased airway epithelial cell death and ciliary cessation. Human bronchial epithelial cells were exposed to epoprostenol in glycine and arginine diluents or control fluid. Ciliary beat frequency, lactate dehydrogenase, and total RNA levels were measured before and after exposure. Results were compared between exposure and control groups. Ciliary beat frequency ceased immediately after exposure to epoprostenol with both diluents. Lactate dehydrogenase levels increased by 200% after exposure to epoprostenol and glycine diluent ( = .002). Total RNA levels were undetectable after exposure to epoprostenol and arginine, indicating complete cell death and lysis ( = .015). Ciliary beat frequency ceased after 30 s of exposure to epoprostenol and glycine ( = .008). There was no difference between cells exposed to epoprostenol and those exposed only to diluent. Exposure to intravenous formulations of epoprostenol in glycine and arginine caused increased cell death and ciliary cessation in bronchial epithelial cells. These findings suggest that undesired local effects may occur when these compounds are delivered as inhaled aerosols to patients.</description><subject>Administration, Inhalation</subject><subject>Analysis</subject><subject>Antihypertensive Agents - adverse effects</subject><subject>Care and treatment</subject><subject>Cell death</subject><subject>Epithelium</subject><subject>Epoprostenol</subject><subject>Epoprostenol - therapeutic use</subject><subject>Glycine</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension, Pulmonary - drug therapy</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - therapeutic use</subject><subject>RNA</subject><subject>Vasodilation</subject><subject>Vasodilator Agents</subject><issn>0020-1324</issn><issn>1943-3654</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNptUc1LwzAUD6K4Ob16lILgrTNp-pEex9h0MNDD9CSUNHlxkbYpSevYf2_cnCiMd3i89_vg8X4IXRM8jgnL7i24VnALY5zllJ2gIcljGtI0iU_REOMIh4RG8QBdOPfhxzRO8nM0oFFCGGZsiN6WRvAqmCkFonOBUcFqY4JF01n-CY3pXTA3tu4r3mnT7PDnvqpNw-02eOXOSO0hYz3SBBNtN3wbzFrdraHSfX2JzhSvHFz99BF6mc9W08dw-fSwmE6WoaCMdSGRpWCpIDLheZ4pXErBQCqepDgCUkoqReZRkUkJtPSbHGguKUjKJBCe0RG63fu-8woK3Sjjzxe1dqKYpJTFNIsT6lnjIyxfEmotTANK-_0_wd0fwRp41a2dqfrdK446C2ucs6CK1urav6gguPiOqTjEVOxi8oKbvaDtyxrkL_2QC_0C2BiQ-w</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Kuch, Bradley A</creator><creator>Linssen, Rosalie</creator><creator>Yoshikawa, Hiroki</creator><creator>Smallwood, Craig D</creator><creator>Davis, Michael D</creator><general>Daedalus Enterprises, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>202010</creationdate><title>Local Effects of Two Intravenous Formulations of Pulmonary Vasodilators on Airway Epithelium</title><author>Kuch, Bradley A ; Linssen, Rosalie ; Yoshikawa, Hiroki ; Smallwood, Craig D ; Davis, Michael D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-1dbc86c1d5a997f0bdc8edfa5602e1bd3dc7c1dc7dde3be1b9e39d3ed38de1a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Administration, Inhalation</topic><topic>Analysis</topic><topic>Antihypertensive Agents - adverse effects</topic><topic>Care and treatment</topic><topic>Cell death</topic><topic>Epithelium</topic><topic>Epoprostenol</topic><topic>Epoprostenol - therapeutic use</topic><topic>Glycine</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension, Pulmonary - drug therapy</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - therapeutic use</topic><topic>RNA</topic><topic>Vasodilation</topic><topic>Vasodilator Agents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kuch, Bradley A</creatorcontrib><creatorcontrib>Linssen, Rosalie</creatorcontrib><creatorcontrib>Yoshikawa, Hiroki</creatorcontrib><creatorcontrib>Smallwood, Craig D</creatorcontrib><creatorcontrib>Davis, Michael D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Respiratory care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kuch, Bradley A</au><au>Linssen, Rosalie</au><au>Yoshikawa, Hiroki</au><au>Smallwood, Craig D</au><au>Davis, Michael D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Local Effects of Two Intravenous Formulations of Pulmonary Vasodilators on Airway Epithelium</atitle><jtitle>Respiratory care</jtitle><addtitle>Respir Care</addtitle><date>2020-10</date><risdate>2020</risdate><volume>65</volume><issue>10</issue><spage>1427</spage><epage>1432</epage><pages>1427-1432</pages><issn>0020-1324</issn><eissn>1943-3654</eissn><abstract>Intravenous formulations of epoprostenol are frequently delivered via nebulizer to treat pulmonary hypertension in acutely ill patients. Although their efficacy as pulmonary vasodilators has been shown to be comparable to inhaled nitric oxide, the local effects of these formulations within the airways have not been determined. We hypothesized that the alkaline diluents of these compounds would lead to increased airway epithelial cell death and ciliary cessation. Human bronchial epithelial cells were exposed to epoprostenol in glycine and arginine diluents or control fluid. Ciliary beat frequency, lactate dehydrogenase, and total RNA levels were measured before and after exposure. Results were compared between exposure and control groups. Ciliary beat frequency ceased immediately after exposure to epoprostenol with both diluents. Lactate dehydrogenase levels increased by 200% after exposure to epoprostenol and glycine diluent ( = .002). Total RNA levels were undetectable after exposure to epoprostenol and arginine, indicating complete cell death and lysis ( = .015). Ciliary beat frequency ceased after 30 s of exposure to epoprostenol and glycine ( = .008). There was no difference between cells exposed to epoprostenol and those exposed only to diluent. Exposure to intravenous formulations of epoprostenol in glycine and arginine caused increased cell death and ciliary cessation in bronchial epithelial cells. These findings suggest that undesired local effects may occur when these compounds are delivered as inhaled aerosols to patients.</abstract><cop>United States</cop><pub>Daedalus Enterprises, Inc</pub><pmid>32518088</pmid><doi>10.4187/respcare.07938</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0020-1324
ispartof Respiratory care, 2020-10, Vol.65 (10), p.1427-1432
issn 0020-1324
1943-3654
language eng
recordid cdi_gale_infotracmisc_A638437453
source Open Access: PubMed Central
subjects Administration, Inhalation
Analysis
Antihypertensive Agents - adverse effects
Care and treatment
Cell death
Epithelium
Epoprostenol
Epoprostenol - therapeutic use
Glycine
Humans
Hypertension
Hypertension, Pulmonary - drug therapy
Nitric oxide
Nitric Oxide - therapeutic use
RNA
Vasodilation
Vasodilator Agents
title Local Effects of Two Intravenous Formulations of Pulmonary Vasodilators on Airway Epithelium
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T16%3A19%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Local%20Effects%20of%20Two%20Intravenous%20Formulations%20of%20Pulmonary%20Vasodilators%20on%20Airway%20Epithelium&rft.jtitle=Respiratory%20care&rft.au=Kuch,%20Bradley%20A&rft.date=2020-10&rft.volume=65&rft.issue=10&rft.spage=1427&rft.epage=1432&rft.pages=1427-1432&rft.issn=0020-1324&rft.eissn=1943-3654&rft_id=info:doi/10.4187/respcare.07938&rft_dat=%3Cgale_cross%3EA638437453%3C/gale_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c388t-1dbc86c1d5a997f0bdc8edfa5602e1bd3dc7c1dc7dde3be1b9e39d3ed38de1a73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/32518088&rft_galeid=A638437453&rfr_iscdi=true